Skip to main content
. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817

Figure 2.

Figure 2

Predictive and prognostic significance of PD-L1 and TMB in PLELC. (A) TMB levels in ICI-treated PLELC-DCB patients versus NDCB patients. (B) Proportion of different PD-L1 expression in DCB patients versus NDCB patients. (C, D) PFS and OS of patients with PD-L1 <1% versus ≥1% in PLELC patients treated with ICI monotherapy. (E, F) PFS and OS of patients with PD-L1 <1% versus ≥1% in PLELC patients treated with ICI combination therapy.